

Adenovirus-Host interactions

**Possible implications for Thrombosis with
Thrombocytopenia Syndrome**

Dr. Alexander T. Baker

bakerat@cardiff.ac.uk

@Protengineer

EMA Virtual Workshop on TTS
27 JUNE 2022

Overview

- Characterization of the ChAdOx1 capsid structure.
- Determination of primary cell entry receptor usage.
- Investigating interactions with Platelet factor 4 (PF4).
- Computational modeling of ChAdOx1/PF4 interactions.
- Down stream implications.

1

Structural Characterization of ChAdOx1



Modeling of ChAdOx1

High Resolution Volume Data

Data sets enabled accurate capsid reconstruction

Interior (top) and exterior (bottom) capsid surfaces show density for all expected proteins

Integrative 'all atom' approach facilitates high confidence simulation of interfaces




Modeling of ChAdOx1

Accurate atomic model placement

Data sets enabled accurate capsid reconstruction

Interior (top) and exterior (bottom) capsid surfaces show density for all expected proteins

Integrative 'all atom' approach facilitates high confidence simulation of interfaces




Modeling of ChAdOx1

Restrained MD simulations

Data sets enabled accurate capsid reconstruction

Interior (top) and exterior (bottom) capsid surfaces show density for all expected proteins

Integrative 'all atom' approach facilitates high confidence simulation of interfaces



2

A Primary Receptor Tropism of ChAdOx1 is CAR


ChAdOx1 uses CAR as a primary receptor

New virus, same receptor



Cell based assays show similar displacement of anti-CAR mAb by ChAdOx1 and Ad5 fiber knob

SPR shows the affinity of CAR is ~100X that of ChAdOx1

mAb Binding Inhibition Assay	CAR IC ₅₀ in CHO-CAR (µg/10 ⁵ cells)	CD46 IC ₅₀ in CHO-BC1 (µg/10 ⁵ cells)
HAdV-C5	0.01	NULL
HAdV-B35	11.86	5.56x10 ⁻⁵
ChAdV-Y25/ChAdOX1	0.08	NULL



SPR	Ligand	K _D (nM)	k _a (1/Ms)	K _d (1/s)
HAdV-C5	CAR	0.06±0.02	1.56±1.07x10 ⁶	1.09±0.7x10 ⁻⁴
ChAdOx1	CAR	7.16±1.92	3.03±0.13x10 ⁴	1.8±0.41x10 ⁻⁴



3

The ChAdOx1 Capsid Interacts with Platelet Factor 4

ChAdOx1 Binds to PF4

Dose dependent and above background


Dose dependent interaction between ChAdOx1 and PF4

Exhibited by 3 clinical adenovirus species

Complex is stable and specific

Complex formation is inhibited by the salt and heparin

ChAdOx1



ChAdOx1 Binds to PF4




Conserved *and* incidental?

Dose dependent interaction
between ChAdOx1 and PF4

Exhibited by 3 clinical adenovirus
species

Complex is stable and specific

Complex formation is inhibited by
the salt and heparin



Virus	Average K_D (nM)
ChAdOx1	661 ± 53
Ad5	789 ± 137
Ad26	301 ± 67

ChAdOx1 Binds to PF4


Capable of tertiary complex formation

Dose dependent interaction
between ChAdOx1 and PF4

Exhibited by 3 clinical adenovirus
species

Complex is stable and specific

Complex formation is inhibited by
the salt and heparin



ChAdOx1 Binds to PF4



Charge dependent

Dose dependent interaction
between ChAdOx1 and PF4

Exhibited by 3 clinical adenovirus
species

Complex is stable and specific

**Complex formation is inhibited
by the salt and heparin**



4


Mechanisms underpinning the adenovirus/PF4 interactions

Mechanism of Interaction


Opposites attract

Adenovirus capsids are negatively charged


ChAdOx1




HAdV-D26




PF4 (Unbound)



PF4 (Heparin)



**Brownian Dynamics (BD) simulations of
platelet factor 4 (PF4) over ChAdOx1**




Mechanism of Interaction

Collisions are not randomly distributed

Adenovirus capsids are negatively charged

Most interactions are at the interfaces between hexons




Mechanism of Interaction

Multiple factors are required

Adenovirus capsids are negatively charged

Most interactions are at the interfaces between hexons

Both charge and shape influence stability



5

Follow-up

Other information


Unpublished and/or preliminary

Questions raised:

1. To what extent is shape complementarity and electrostatic mechanism contributing to this interaction?
2. Is the frequency of interaction relevant to the mechanism of TTS in a biological context above a certain threshold of interaction?
3. Is a tertiary partner affecting the complex?

A hypothesis

- I. An Adenovirus-PF4 complex forms
- II. The complex reaches the lymph
- III. Stimulates proliferation of pre-existing anti-PF4 B-cells and antibody secretion
- IV. Antibody-PF4-Platelet complexes form
- V. Immuno-aggregates stimulate thrombosis, similar to what is observed in HIT



Acknowledgements

Ryan J. Boyd
Daipayan Sarkar
Alicia Teixeira-Crespo
Chun Kit Chan
Emily Bates
Kasim Waraich
John Vant
Eric Wilson
Chloe D. Truong
Magdalena Lipka-Lloyd
Petra Fromme
Josh Vermaas
Dewight Williams

LeeAnn Machiesky
Meike Heurich
Bolni M. Nagalo
Lynda Coughlan
Scott Umlauf
Po-Lin Chiu
Pierre J. Rizkallah
Taylor S. Cohen
Alan L. Parker
Abhishek Singharoy
Mitesh J. Borad



Abhishek Singharoy



Mitesh J. Borad



Alan L. Parker



Alicia Teixeira-Crespo



Ryan J. Boyd



Meike Heurich



Chun Kit Chan



Daipayan Sarkar



John W. Vant

